Previous close | 31.87 |
Open | 31.31 |
Bid | 30.40 x 900 |
Ask | 36.27 x 1200 |
Day's range | 30.77 - 32.14 |
52-week range | 23.00 - 36.30 |
Volume | |
Avg. volume | 336,736 |
Market cap | 8.725B |
Beta (5Y monthly) | 0.72 |
PE ratio (TTM) | 53.50 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.06 (0.19%) |
Ex-dividend date | 07 June 2023 |
1y target est | N/A |
PIOMBINO DESE, Italy, March 26, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previously announced upsized underwritten public offering of an aggregate of 14,605,000 of its ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,905,000 addi
PIOMBINO DESE, Italy, March 22, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
PIOMBINO DESE, Italy, March 20, 2024--Stevanato Group S.p.A. (NYSE: STVN) ("Stevanato Group," or the "Company"), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.